FORM D

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM D

NOTICE OF SALE OF SECURITIES PURSUANT TO REGULATION D, **SECTION 4(6), AND/OR** UNIFORM LIMITED OFFERING EXEMPTION

OMB Number: 3235-0076 Expires: November 30, 2008 Estimated average burden hours per form SEC USE ONLY Prefix Serial DATE RECEIVED

OMB APPROVAL

Name of Offering (check if this is an amendment and name has changed, and indicate change.)
8% Senior Secured Promissory Notes with Common Stock and Common Stock Purchase Warrants
Filing Under (Check box(es) that apply): Rule 504 Rule 505 Rule 506 Rule 4(6) LUCE Type of Filing: New Filing Amendment
A. BASIC IDENTIFICATION DATA
1. Enter the information requested about the issuer
Name of Issuer (check if this is an amendment and name has changed, and indicate change.)
QuantRx Biomedical Corporation
Address of Executive Offices (Number and Street, City, State, Zip Telephone Num 08060805
Code) 100 S. Main Street, Suite 300, Doylestown, PA 18901 (267) 880-1595
Address of Principal Business Operations (Number and Street, City, State, Zip Telephone Number (Including Area Code)
Code)(if different from Executive Offices)
Brief Description of Business QuantRx Biomedical Corporation is engaged in the research and development of medical diagnostics, specializing in creating, acquiring and commercializing diagnostic platforms and developing products based on its core intellectual property, for both professional and consumer use.
Type of Business Organization
☐ corporation ☐ limited partnership, already formed ☐ other (please specify):
business trust limited partnership, to be formed pROCESSED
Month Year
Actual or Estimated Date of Incorporation or Organization: 12 1986 🖂 Actual 🔲 Estimated 💢 EP 2 2 2008
Jurisdiction of Incorporation or Organization: (Enter two-letter U.S. Postal Service abbreviation for State: NV
CN for Canada; FN for other foreign jurisdiction)
GENERAL INSTRUCTIONS
Federal: Who Must File: All issuers making an offering of securities in reliance on an exemption under Regulation D or Section 4(6), 17 CFR 230.501 et seq. Or 15 U.S.C. 77d(6).
When To File: A notice must be filed no later than 15 days after the first sale of securities in the offering. A notice is deemed filed with the U.S. Securities and Exchange Commission (SEC) on the earlier of the date it is received by the SEC at the address given below or, if received at that address after the date on which it is due, on the date it was mailed by United States registered or certified mail to that address.
Where to File: U.S. Securities and Exchange Commission, 450 Fifth Street, N.W., Washington, D.C. 20549.
Copies Required: Five (5) copies of this notice must be filed with the SEC, one of which must be manually signed. Any copies not manually signed must be photocopies of the manually signed copy or bear typed or printed signatures.
Information Required: A new filing must contain all information requested. Amendments need only report the name of the issuer and offering, any changes thereto, the information requested in Part C, and any material changes from the information previously supplied in Parts A and B. Part E and the Appendix need not be filed with the SEC.
Filing Fee: There is no federal filing fee.
State: This notice shall be used to indicate reliance on the Uniform Limited Offering Exemption (ULOE) for sales of securities in those states that have adopted ULOE and that have adopted this form. Issuers relying on ULOE must file a separate notice with the Securities Administrator in each state where sales are to be, or have been made. If a state requires the payment of a fee as a precondition to the claim for the exemption, a fee in the proper amount shall accompany this form. This notice shall be filed in the appropriate states in accordance with state law. The Appendix to the notice constitutes a part of this notice and must be completed.
ATTENTION Failure to file motion in the commonwists states will not result in a less of the federal exemption. Conversely, failure
Failure to file notice in the appropriate states will not result in a loss of the federal exemption. Conversely, failure to file the appropriate federal notice will not result in a loss of an available state exemption unless such exemption is predicted on the filing of a federal notice.

2. Enter the information requested for the following:	
 Each promoter of the issuer, if the issuer has been organized within the past five years; 	
• Each beneficial owner having the power to vote or dispose, or direct the vote or disposition of, 10% or more of a class of	of
equity securities of the issuer;	
 Each executive officer and director of corporate issuers and of corporate general and managing partners of partnershi issuers; and 	p
Each general and managing partner of partnership issuers.	
Check Box(es) that Apply: Promoter Beneficial Owner Executive Officer Director General and/or Managing Partner	
Full Name (Last name first, if individual)	
WITOSHKIN, WALTER	
Business or Residence Address (Number and Street, City, State, Zip Code)	
c/o QuantRx Biomedical Corporation, 100 S. Main Street, Suite 300, Doylestown, PA 18901	
Check Box(es) that Apply: Promoter Beneficial Owner Executive Officer Director General and/or Managing Partner	
Full Name (Last name first, if individual)	_
FLEMING, WILLIAM H.	
Business or Residence Address (Number and Street, City, State, Zip Code)	
c/o QuantRx Biomedical Corporation, 100 S. Main Street, Suite 300, Doylestown, PA 18901	
Check Box(es) that Apply: Promoter Beneficial Owner Executive Officer Director General and/or Managing Partner	
Full Name (Last name first, if individual)	
AFANASSIEV, SASHA	
Business or Residence Address (Number and Street, City, State, Zip Code)	_
c/o QuantRx Biomedical Corporation, 100 S. Main Street, Suite 300, Doylestown, PA 18901	
Check Box(es) that Apply: Promoter Beneficial Owner Executive Officer Director General and/or Managing Partner	
Full Name (Last name first, if individual)	
HORTON, CYNTHIA	
Business or Residence Address (Number and Street, City, State, Zip Code)	_
c/o QuantRx Biomedical Corporation, 100 S. Main Street, Suite 300, Doylestown, PA 18901	
Check Box(es) that Apply: Promoter Beneficial Owner Executive Officer Director General and/or Managing Partner	
Full Name (Last name first, if individual)	_
HIRSCHMAN, SHALOM	
Business or Residence Address (Number and Street, City, State, Zip Code)	
c/o QuantRx Biomedical Corporation, 100 S. Main Street, Suite 300, Doylestown, PA 18901	
Check Box(es) that Apply: Promoter Beneficial Owner Executive Officer Director General and/or Managing Partner	
Full Name (Last name first, if individual)	_
HULL HAYES, ARTHUR, JR.	
Business or Residence Address (Number and Street, City, State, Zip Code)	
c/o QuantRx Biomedical Corporation, 100 S. Main Street, Suite 300, Doylestown, PA 18901	

A. BASIC IDENTIFICATION DATA

Check Box(es) that Apply:	Promoter N	Beneficial Owner fanaging Partner	Executive Officer	Director	General and/or					
Full Name (Last name first, if individual)										
BALK, MATTHEW										
Business or Residence Address	s (Number and S	Street, City, State, Zip Co	ode)							
570 Lexington Avenue, New	York, NY 10021									
Check Box(es) that Apply:	Promoter N	Beneficial Owner lanaging Partner	Executive Officer	Director	General and/or					
Full Name (Last name first, if	individual)	· · · · · · · · · · · · · · · · · · ·								
SHERBROOKE PARTNERS	, LLC									
Business or Residence Addres	Business or Residence Address (Number and Street, City, State, Zip Code)									
570 Lexington Avenue, New York, NY 10021										
(L	Ise blank sheet, o	or copy and use additiona	l copies of this sheet, as n	ecessary.)						

					B. IN	FORMA'	TION ABO	OUT OFF	ERING				
													Yes No
1.	Has t	the issuer	sold, or do	es the issu	er intend to	sell, to no	on-accredit	ed investo	rs in this o	ffering:			
				Α	nswer also	in Append	lix, Colum	n 2, if filin	g under Ul	LOE			
2.	What	t is the mi	nimum in	vestment th	at will be a	accepted fr	om anv in	dividual:					N/A
						-							Yes No
3.	Does	the offer	ing permit	joint owne	ership of a	single unit	?					•••••	
4.	Enter	r the info	rmation re	auested fo	r each pers	on who h	as been or	will be pa	aid or give	n. directly	or indirect	tly, any	
					on for sol								
					an associat								
					of the brol							sociated	
					you may se	t forth the	informatio	on for that	broker or o	leater only.			
		•	•	f individua	1)								
			CRD # 117										
Bus	iness	or Reside	nce Addre	ss (Numbe	r and Stree	t, City, Sta	ite, Zip Co	de)					
					NY 10019								
Nar	ne of .	Associate	d Broker o	r Dealer									
Stat	es in	Which Pe	rson Liste	d Has Solid	ited or Inte	ends to So	icit Purcha						
.		•			ndividual S	•		All Sta					
[AL	-	[AK]	[AZ]	[AR]	(CA) x	[CO]	[CT]	[DE]	[DC]	[FL]	[GA]	[HI]	[ID]
[IL]	-	[IN]	[IA]	[KS]	[KY]	[LA]	[ME]	[MD]	[MA]	[MI]	[MN]	[MS] [OR]	[MO] [PA]
[M]		[NE] [SC]	[NV] [SD]	[NH] [TN]	[NJ] x [TX] x	[NM] [UT] x	[NY] x [VT]	[NC] [VA]	[ND] [WA]	[OH] [WV]	[OK] [WI]	[WI]	[PR]
				f individua		<u>[O.J.i.</u>		[• • • •]	[,,,,,,	14.11		[17 -]	[]
		`	,		,								
Bus	iness	or Reside	nce Addre	ss (Numbe	r and Stree	t. City. Sta	te. Zip Co	de)					
						, ,	, _ [
Nar	ne of .	Associate	d Broker o	r Dealer									
Stat	es in '	Which Pe	rson Lister	1 Has Solic	ited or Inte	ends to Sol	icit Purcha	nsers			_		
					idividual S			All Sta	ites				
[AL	_[ر	[AK]	[AZ]	[AR]	[CA]	[CO]	[CT]	[DE]	[DC]	[FL]	[GA]	[HI]	[ID]
[IL]		[IN]	[IA]	[KS]	[KY]	[LA]	[ME]	[MD]	[MA]	[MI]	[MN]	[MS]	[MO]
[M [*]		[NE]	[NV]	[NH]	[NJ]	[NM]	[NY]	[NC]	[ND]	[OH]	[OK]	[OR]	[PA]
[RI]		[SC]	[SD]	[TN] f individua	[TX]	[UT]	[VT]	[VA]	[WA]	[WV]	[WI]	[WI]	[PR]
run	INAIII	e (Last na	une mst, i	i ilidividua	1)								
D		D:4-	4	Alh -	r and Stree	4 Cit. Ct	4- 7:- C-	١-١					
Bus	iness	or Reside	nce Addre	ss (Numbe	r and Stree	ı, City, Sta	ite, Zip Co	ae)					
3.1			1.0										
ivar	ne of A	Associate	d Broker o	r Dealer									
0		O. 71. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1		111 0 "	A.A. T.	1-4 0 3	1-14 D						
Stat					ited or Intendividual S		icit Purcha	isers All Sta	ites				
[AL		[AK]	[AZ]	[AR]	[CA]	[CO]	[CT]	[DE]	[DC]	[FL]	[GA]	[HI]	[ID]
[IL]		[IN]	[A]	[KS]	[KY]	[LA]	[ME]	[MD]	[MA]	[MI]	[MN]	[MS]	[MO]
[M]	Γ]	[NE]	[NV]	[HN]	[NJ]	[MM]	[NY]	[NC]	[ND]	[OH]	[OK]	[OR]	[PA]
[RI]	1	[SC]	(SD)	[TN]	[TX]	[TIT]	(VT)	[VA]	[WA]	[WV]	(WI)	[WI]	[PR]

(Use blank sheet, or copy and use additional copies of this sheet, as necessary.)

	C. OFFERING PRICE, NUMBER OF INVESTORS, EXPENSES AND USE O	OF PROCEEDS	S
1.	Enter the aggregate offering price of securities included in this offering and the total amount already sold. Enter "0" if answer is "none" or "zero." If the transaction is an exchange offering, check this box and indicate in the columns below the amounts of the securities offered for exchange and already exchanged.	Aggregate	Amount
	Type of Security	Offering Price	Already Sold
	Debt	0	0
	Equity	0	0
	☐ Common ☐ Preferred		
	Convertible Securities (including warrants)	0	0
	Partnership Interests	0	0
	Other (Specify)Senior Secured Promissory Notes with Common Stock and Common Stock Purchase Warrants	\$550,000	\$550,000
	Total	\$550,000	\$550,000
	Answer also in Appendix, Column 3, if filing under ULOE.		
2.	Enter the number of accredited and non-accredited investors who have purchased securities in this offering and the aggregate dollar amounts of their purchases. For offerings under Rule 504, indicate the number of persons who have purchased securities and the aggregate dollar amount of their purchases on the total lines. Enter "0" if answer is "none" or "zero."		Aggregate
		Number Investors	Dollar Amount of Purchases
	Accredited Investors	7	\$550,000
	Non-accredited Investors	0	\$0
	Total (for filings under Rule 504 only)	n/a	n/a
	Answer also in Appendix, Column 4, if filing under ULOE.		
3.	If this filing is for an offering under Rule 504 or 505, enter the information requested for all securities sold by the issuer, to date, in offerings of the types indicated, in the twelve (12) months prior to the first sale of securities in this offering. Classify securities by type listed in Part C - Question 1		
		Type of	Dollar Amount
	Type of offering	Security	Sold
	Rule 505	n/a	n/a
	Regulation A	n/a	n/a
	Rule 504	n/a	n/a
	Total	n/a	n/a
4.	a. Furnish a statement of all expenses in connection with the issuance and distribution of the securities in this offering. Exclude amounts relating solely to organization expenses of the issuer. The information may be given as subject to future contingencies. If the amount of an expenditure is not known, furnish an estimate and check the box to the left of the estimate.		
	Transfer Agent's Fee		\$
	Printing and Engraving Costs		\$
	Legal Fees		\$
	Accounting Fees		\$
	Engineering Fees		\$
	Sales Commissions (specify finders' fees separately)	\boxtimes	\$55,000*
	Other Expenses (identify)		\$
	Total	\boxtimes	\$55,000
* E	scludes 100,000 common stock purchase warrants, each with a term of 5 years and an exercise price of \$0.85.	— -	·

C. OFFERING PRICE, NUMBER OF INVESTORS, EXPENSES AND USE OF PROCEEDS

5.	b. Enter the difference between the aggregate Question 1 and total expenses furnished in resp is the "adjusted gross proceeds to the issuer." Indicate below the amount of the adjusted gross used for each of the purposes shown. If the amestimate and check the box to the left of the esequal the adjusted gross proceeds to the issuer above.	onse to Part C - Question 4.a. This difference s proceeds to the issuer used or proposed to be count for any purpose is not known, furnish an timate. The total of the payments listed must		\$495,000
			Payments to Officers, Directors, & Affiliates	Payments To Others
			 \$	□\$
		of machinery and equipment		<u></u> \$
		nd facilities	\$	 \$
the	Acquisition of other businesses (including offering that may be used in exchange for pursuant to a merger)	the value of securities involved in this the assets or securities of another issuer d)	ssss this notice is file and Exchange 6	Commission, upon
wri 502	tten request of its staff, the information furnished	d by the issuer to any non-accredited investor p	ursuant to paragi	raph (b)(2) of Rule
Iss	uer (Print or Type)	Signature V OV.	Date	•
	antRx Biomedical Corporation	m	September	2 , 2008
	me of Signer (Print or Type)	Title of Signer (Print or Type)		
Sas	sha Afanassiev	Chief Financial Officer, Treasurer & Vice	President of Fin	iance
	ontional misstatements or omissions of f	ATTENTION	40 40 110	0.4004.)

	E. STATE SIGNATURE								
1.	Is any party described in 17 CFR 230.252(c), (d), (e) or (f) presently subject to any of the disqualification Yes No ¹ provisions or such rule?								
	See Appendix, Column 5 for state response.								
2	The understand issuer hereby undertakes to furnish to any state administrator of any state in which this notice is filed, a notice on								

- 2. The undersigned issuer hereby undertakes to furnish to any state administrator of any state in which this notice is filed, a notice on Form D (17 CFR 239.500) at such times as required by state law.
- 3. The undersigned issuer hereby undertakes to furnish to the state administrators, upon written request, information furnished by the issuer to offerees.
- 4. The undersigned issuer represents that the issuer is familiar with the conditions that must be satisfied to be entitled to the Uniform Limited Offering Exemption (ULOE) of the state in which this notice is filed and understands that the issuer claiming the availability of this exemption has the burden of establishing that these conditions have been satisfied.

The issuer has read this notification and knows the contents to be true and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

	N N N	
Issuer (Print or Type)	Signature	
QuantRx Biomedical Corporation	September 0, 2008	
Name of Signer (Print or Type)	Title of Signer (Print or Type)	
Sasha Afanassiev	Chief Financial Officer, Treasurer & Vice President of Finance	

Instruction:

Print the name and title of the signing representative under his signature for the state portion of this form. One copy of every notice on Form D must be manually signed. Any copies not manually signed must be photocopies of the manually signed copy or bear typed or printed signatures.

¹ Not applicable to Rule 506 offerings.

APPENDIX

[2	3			4			
1	Intend to sell to non- accredited investors in State (Part B-Item 1)		Type of security and aggregate offering price offered in state (Part C-Item 1)		Type of investor and amount purchased in State (Part C-Item 2)				ification ate ULOE , attach ation of granted) -Item 1)
State	Yes	No	Senior Secured Promissory Notes with Common Stock and Common Stock Purchase Warrants (\$550,000)	Number of Accredited Investors	Amount	Number of Non-Accredited Investors	Amount	Yes	No
AL					· · · · · · · · · · · · · · · · · · ·			_	_
AK						_	·		
AZ							·		
AR									
CA		Х	Senior Secured Promissory Notes with Common Stock and Common Stock Purchase Warrants (\$550,000)	2	\$200,000	0	0		(2)
со								ļ	
СТ									
DE									
DC								<u> </u>	
FL								ļ	
GA									
HI									
ID									
IL									
IN								<u> </u>	
IA									
KS									
KY									
LA									
ME									ļ
MD									
MA			1.606.60						

⁽²⁾ Not applicable to Rule 506 offerings.

1		2	3			4		· ·	5		
	Intend to sell to non- accredited investors in State (Part B-Item 1)		Type of security and aggregate offering price offered in state (Part C-Item 1)	Type of investor and amount purchased in State (Part C-Item 2)					Disqualification under State ULOE (if yes, attach explanation of waiver granted) (Part E-Item 1)		
State	Yes	No	Senior Secured Promissory Notes with Common Stock and Common Stock Purchase Warrants (\$550,000)	Number of Accredited Investors	Amount	Number of Non-Accredited Investors	Amount	Yes	No		
MI											
MN											
MS											
МО			:								
MT											
NE											
NV											
NH											
NJ		х	Senior Secured Promissory Notes with Common Stock and Common Stock Purchase Warrants (\$550,000)	1	\$25,000	0	0		(2)		
NM											
NY		x	Senior Secured Promissory Notes with Common Stock and Common Stock Purchase Warrants (\$550,000)	1	\$50,000	0	0		(2)		
NC											
ND											
ОН											
OK											
OR											
PA											
RI											
SC											
SD											
TN											

⁽²⁾ Not applicable to Rule 506 offerings.

1		2	3		4						
	Intend to sell to non- accredited investors in State (Part B-Item 1)		Type of security and aggregate offering price offered in state (Part C-Item 1)		Type o amount pr (Par	explana waiver	, attach ation of granted) -Item 1)				
State	Yes	No	Senior Secured Promissory Notes with Common Stock and Common Stock Purchase Warrants (\$550,000)	Number of Accredited Investors	Amount	Number of Non-Accredited Investors	Amount	Yes	No		
TX		х	Senior Secured Promissory Notes with Common Stock and Common Stock Purchase Warrants (\$550,000)	1	\$200,000	0	0		(2)		
UT		x	Senior Secured Promissory Notes with Common Stock and Common Stock Purchase Warrants (\$550,000)	2	\$75,000	0	0		(2)		
VT											
VA											
WA											
wv											
WI		_									
WY											
PR											
Over- seas											

⁽²⁾ Not applicable to Rule 506 offerings.